20, 2012 /PRNewswire/ -- PROTEONOMIX, INC. , a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that the in conjunction with the Company has commenced the screening of patients with End Stage Liver Disease for use in its clinical trial of UMK-121. , the Chief Executive ... (more)
http://www.biospace.com/news_story.aspx?StoryID=280299&full=1
http://www.biospace.com/news_story.aspx?StoryID=280299&full=1
No comments:
Post a Comment